EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic microRNAs: Mechanisms, Delivery, and Clinical Translation in Oncology

Humberto Vélez-Slimani, Luis A Salazar iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27052162 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Humberto Vélez-Slimani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program in Sciences Major in Applied Cellular and Molecular Biology, Universidad de La Frontera, Temuco 4811230, Chile. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de La Frontera.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MicroRNAs (miRNAs) are ~19–25-nt post-transcriptional regulators whose dysregulation promotes hallmark cancer traits and therapy resistance. This review synthesizes translational principles for developing miRNA therapeutics in oncology, integrating miRNA biology and target engagement with delivery design and clinical experience. We summarize key determinants that shape efficacy and safety, including sequence and chemistry choices, biodistribution and intracellular delivery, dosing strategy, and biomarker-informed patient selection. We compare the main therapeutic modalities, miRNA mimics and inhibitors, and evaluate leading delivery approaches relevant to cancer, including lipid-based systems, polymer-based carriers and conjugates, and extracellular vesicle-inspired platforms, highlighting trade-offs in stability, specificity, immune activation, and tumor exposure. Early clinical programs such as MRX34, TargomiR/MesomiR-1, and cobomarsen, together with experience from non-oncology indications, illustrate both opportunities and practical constraints on tolerability and regimen optimization. We conclude with pragmatic priorities for the field, including standardized analytics for isoforms and target engagement, PK/PD- and biomarker-guided dose selection, and rational combination strategies to safely integrate miRNA-based interventions into precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsNeoplasmsHumansAnimalsTranslational Research, BiomedicalExtracellular Vesicles

Stichwörter der Autor:innen

clinical translationextracellular vesiclesmiRNA deliverymicroRNA therapeuticsoligonucleotide chemistrytarget engagement

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Doctoral Program in Sciences Major in Applied Cellular and Molecular Biology, Universidad de La Frontera, Temuco 4811230, Chile.
  • Center for Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Universidad de La Frontera, Temuco 4811230, Chile.

ORCID-Profile: Luis A Salazar

Förderung

  • Universidad de La Frontera

Zitieren

APA

Vélez-Slimani, H., & Salazar, L. A. (2026). Therapeutic microRNAs: Mechanisms, Delivery, and Clinical Translation in Oncology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27052162

Vancouver

Vélez-Slimani H, Salazar LA. Therapeutic microRNAs: Mechanisms, Delivery, and Clinical Translation in Oncology. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27052162

BibTeX
@article{VlezSlimani2026,
  author = {Vélez-Slimani, Humberto and Salazar, Luis A},
  title = {Therapeutic microRNAs: Mechanisms, Delivery, and Clinical Translation in Oncology},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27052162}
}
Kostenlos starten →